Pillar · Performance research
Muscle, Recovery and Performance Peptide Research
This hub covers peptides studied against musculoskeletal and exercise-physiology endpoints: muscle protein synthesis, satellite-cell activity, connective-tissue remodelling and recovery markers after loading. It also covers why almost none of this work supports performance claims in trained humans, and how anti-doping regulation treats the category.
Evidence position
Mostly preclinical
Research evidence, established clinical evidence and regulatory approval are three different things. This page distinguishes them throughout and does not present research compounds as approved treatments.
Endpoints that matter
Muscle research distinguishes between acute signalling changes — mTOR pathway phosphorylation, myofibrillar protein synthesis rates measured with stable isotope tracers — and functional outcomes such as cross-sectional area, strength or time-to-return-to-sport. Signalling changes are easy to produce and frequently do not translate into functional change.
Growth hormone axis versus direct anabolic signalling
Secretagogue peptides act indirectly, prompting endogenous growth hormone release, which raises IGF-1. Whether that indirect route produces meaningful change in lean mass or function in healthy trained adults is not established by the current human literature, and the studies that do exist frequently measure body composition rather than performance.
Anti-doping status
Many peptides in this hub appear on the World Anti-Doping Agency prohibited list, including growth hormone secretagogues and related agents. Athletes in tested sport should treat the entire category as prohibited unless they have verified otherwise against the current list.
Compounds studied in this area
| Compound | What it is | Evidence tier |
|---|---|---|
| Growth hormone secretagogues | Peptides that stimulate endogenous GH release; studied in body-composition endpoints. | Emerging human research |
| IGF-1 and analogues | Downstream mediator of GH signalling; extensively characterised biologically, tightly regulated. | Established clinical evidence |
| BPC-157 | Studied in rodent muscle-crush and tendon models; no controlled human recovery data. | Mostly preclinical |
| TB-500 | Actin-binding fragment studied in cell-migration and repair models. | Mostly preclinical |
Comparisons in this cluster
Key takeaways
- This hub covers peptides studied against musculoskeletal and exercise-physiology endpoints: muscle protein synthesis, satellite-cell activity, connective-tissue remodelling and recovery markers after loading. It also covers why almost none of this work supports performance claims in trained humans, and how anti-doping regulation treats the category.
- Overall evidence position for this topic: mostly preclinical.
- Findings in cells or animals are hypotheses about humans, never demonstrations in humans.
- Nothing on this page is medical advice, a protocol, or a dosing recommendation.
Frequently asked questions
Do peptides build muscle?
No peptide in this category has been shown in controlled human trials to increase strength or performance in trained adults. Some influence body composition markers through the growth hormone axis, which is a different claim.
Are these compounds allowed in tested sport?
Generally no. Growth hormone secretagogues and related peptides appear on the WADA prohibited list.
Continue reading
Related research hubs
Regenerative Peptides
BPC-157, TB-500, GHK-Cu and related sequences studied in tendon, ligament, muscle and wound-healing models — mechanisms, evidence tiers and honest limitations.
Growth Hormone & Secretagogue Peptides
GHRH analogues and ghrelin-receptor secretagogues explained — pulsatility, IGF-1 mediation, comparative pharmacology and regulatory status.
Peptide Safety
What is actually known about peptide safety — immunogenicity, contamination, unknown long-term profiles, and why absence of reported harm is not evidence of safety.
Peptide Comparisons
Head-to-head peptide comparisons built on evidence tables — mechanism, pharmacology, study base and limitations, without unsupported superiority claims.
About this page
Written and reviewed by the Peptide Intel Hub Editorial Team. Last reviewed 8 September 2026.
Scientific disclaimer: this page is educational and does not constitute medical advice. Research compounds referenced here are not approved treatments. See our research disclaimer.